The European Society for Sexual Medicine (ESSM) is Europe's leading scientific organization in sexual medicine whose annual conference brings together prominent researchers and doctors from all over the world. The ESSM Scientific Council has selected Dicot's preclinical study results for presentation at the next conference taking place in the Italian city of Bari on February 8-10, 2024.

"Interest in Dicot's development work seems to be growing more and more. This time we were personally encouraged by ESSM's chairman to come and present our results. It is the third year in a row that we have been handpicked for the conference, which I think is a clear proof of Dicot's level of innovation and our candidate's news value," says Elin Trampe, CEO of Dicot.

For further information, please contact:

Elin Trampe, CEO

Phone: +4672502 10 10

E-mail: elin.trampe@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 4,900 shareholders. For more information, please visit www.dicot.se.